MedTrace Logo

Intranasal Insulin for Posttraumatic Stress Disorder

NCT04044534 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2025-09-16

No results posted yet for this study

Summary

To evaluate if intranasal insulin is effective in reducing PTSD symptoms.

Conditions

Interventions

DRUG

Intranasal insulin

Subjects in this arm will receive intranasal insulin (80 IU per day).

DRUG

Placebo

Subjects in this arm will receive placebo.

Sponsors & Collaborators

  • VA Connecticut Healthcare System

    lead FED

Principal Investigators

  • Gihyun Yoon, MD · VA Connecticut Healthcare System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-31
Primary Completion
2026-05-31
Completion
2026-05-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04044534 on ClinicalTrials.gov